Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer
|
|
- Leonard Foster
- 6 years ago
- Views:
Transcription
1 Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Ethan J. Halpern 1 Stephen E. Strup 2 OBJECTIVE. We performed a prospective study to assess gray-scale and color and power Doppler sonography for the detection of prostatic cancer and to determine the impact of operator experience. SUBJECTS AND METHODS. Four radiologists with prior experience using gray-scale and Doppler imaging and four urologists with prior experience limited to gray-scale imaging performed sextant biopsies on 251 patients. Each biopsy site was prospectively scored for gray-scale and Doppler abnormality. RESULTS. Cancer was detected in 211 biopsy sites from 85 patients. Overall agreement between sonographic findings and biopsy results as measured with the kappa statistic was minimally superior to chance (κ = 0.12 for gray-scale, κ = 0.11 for color Doppler, κ 0.09 for power Doppler). With respect to gray-scale diagnosis of cancer, the performance of radiologists (κ = 0.12) and urologists (κ = 0.13) was similar. With respect to power Doppler, the performance of radiologists (κ = 0.09) was superior to that of urologists (κ = 0.03, p < 0.002). Among patients with at least one positive biopsy for cancer, foci of increased power Doppler flow detected by a radiologist were 4.7 times more likely to contain cancer than adjacent tissues without flow. CONCLUSION. Gray-scale and Doppler imaging did not reveal prostatic cancer with sufficient accuracy to avoid sextant biopsy. Power Doppler may be useful for targeted biopsies when the number of biopsy passes must be limited. There is benefit from increased operator experience with Doppler imaging, but there is no demonstrable benefit of power Doppler over conventional color Doppler sonography. Received June 24, 1999; accepted after revision August 10, Department of Radiology, Jefferson Prostate Center, Thomas Jefferson University, 132 S. 10th St., Philadelphia, PA Address correspondence to E. J. Halpern. 2 Department of Urology, Jefferson Prostate Center, Thomas Jefferson University, Philadelphia, PA AJR 2000;174: X/00/ American Roentgen Ray Society T he number of new cases of prostatic cancer in the United States in 1999 is estimated at 179,300 with 37,000 resulting in death [1]. Assuming one third of prostate biopsies reveal cancer, more than 500,000 prostate biopsies are performed annually. Although most clinicians use sonography to guide the biopsy, differences of opinion exist with regard to the role of sonography [2]. Only 20% of urologists perform targeted biopsy on the basis of sonographic findings [3]. Cancer of the prostate classically presents as a hypoechoic lesion [4] but can appear echogenic or isoechoic [5]. Although increased cancer detection has been reported with color Doppler sonography [6 8], the combined sensitivity of gray-scale and color Doppler imaging is insufficient to preclude sextant biopsy [9 11]. Power Doppler is more sensitive to slow flow and is less angledependent than color Doppler imaging [12]. Results of several small studies have suggested that power Doppler sonography may be useful in detection of prostatic cancer [13,14]. To our knowledge, no large series has evaluated power Doppler imaging for the detection of prostatic cancer, and no study has directly compared color and power Doppler sonography of the prostate. Our study correlates findings on grayscale and color and power Doppler imaging with results from sextant biopsy. The focus is to evaluate the diagnostic accuracy of power Doppler sonography and the impact of operator experience on the Doppler examination. Subjects and Methods Our study population consisted of 251 patients who underwent sonographically guided biopsy of the prostate between October 1997 and June Patients ranged in age from 37 to 87 years, with a AJR:174, March
2 Halpern and Strup mean age of 64.6 years. The serum level of prostate-specific antigen (PSA) was available for 223 patients and was elevated (>4 ng/dl) in 190. A PSA value of greater than 10 was found in 53 patients. The average PSA value was 8.7 ng/dl. All patients were examined with the 6.5EC10 endfire probe using the Sonoline Elegra system (Siemens; Issaquah, WA). For gray-scale imaging, the center probe frequency was 6.0 MHz with a dynamic range of 55 db. For color and power imaging, the center probe frequency was 4.0 MHz with a dynamic range of 30 db, pulse repetition frequency was 868 Hz, and wall filter was set to low. Color and power gain were adjusted as follows: gain was increased until clutter was observed and then reduced just enough to remove clutter from the prostate. Transrectal examination consisted of a standard sequence of axial images from base to apex, followed by sagittal images from right to left. Sextant biopsy of the outer gland was performed on all patients. Six independent biopsy specimens from the outer gland were obtained from each patient. Individual biopsy specimens were obtained from the base, mid gland, and apex on each side of the gland. When an abnormality was visualized on gray-scale or Doppler imaging, the corresponding sextant biopsy was directed to the site of the abnormality. An 18- gauge core biopsy system (ASAP; Medi-tech, Boston Scientific, Watertown, MA) was used. The imaging protocol changed in 1998 when the departments of radiology and urology formed a joint prostate imaging center. In the 3 months before formation of this joint center, 41 patients were examined by one of four experienced radiologists using grayscale and color Doppler sonography. These 41 patients were our baseline for color Doppler imaging. During 1998, four experienced urologists were added to the prostate center staff. Although each of the radiologists and urologists was experienced with gray-scale sonography, the urologists had no prior experience with Doppler imaging. Between January 1998 and June 1999, 210 patients were examined with gray-scale and power Doppler sonography. Sonographic findings were recorded at the base, mid portion, and apex of the gland on both the right and left sides. Gray-scale was classified as normal, indeterminate, or abnormal at each biopsy site. A normal site was homogeneous in texture with no focal contour bulge. A site was classified as abnormal if a definite mass, either echogenic or hypoechoic, was present. Doppler flow was subjectively classified as absent, minimal, or increased at each biopsy site. Imaging findings were scored prospectively at the time of the examination. For statistical analysis, indeterminate gray-scale findings were classified as abnormal and minimal Doppler flow was classified as increased. A kappa value was computed to document the agreement between sonographic findings and pathology. The kappa value quantifies the level of agreement relative to that which might be expected by chance. A kappa value of 1 corresponds to perfect disagreement, whereas a kappa value of +1 corresponds to perfect agreement. A kappa value of 0 corresponds to chance agreement. Although the kappa value is generally used to assess agreement between two observers, we have expanded its application to assess agreement between sonographic findings and needle biopsy results. The advantage of the kappa value over the traditional measures of diagnostic accuracy lies in its ability to assess observer performance relative to random agreement. To determine the value of sonography in selecting the biopsy site in patients with cancer, conditional logistic regression was applied. Conditional logistic regression allows matching of biopsy sites within each patient and accounts for the lack of independence of multiple sites within an individual patient. Statistical analyses were performed for the entire patient population and were repeated for various subsets of patients. All statistical computations were performed with Stata 6.0 software (Stata, College Station, TX). Results Malignant tissue was found in a total of 211 biopsy sites of 85 patients. Gleason scores ranged from 3 to 10, with a mean value of 6.7. The most common Gleason scores were 6, 7, and 8, which accounted for 38%, 33%, and 14% of all malignancies, respectively. Grayscale and color or power Doppler abnormalities were often associated with the presence of prostatic cancer (Figs. 1 and 2). With respect to the detection of malignant lesions (Table 1), gray-scale sonography yielded 44.1% sensitivity with 73.6% specificity (κ = 0.12), whereas Doppler imaging (color and power) yielded 27.0% sensitivity with 77.1% specificity (κ = 0.03). Thirty-five of the 211 lesions were detected with both gray-scale and Doppler imaging, but 96 lesions were missed by both these techniques. Even among patients with a PSA level of greater than 10 ng/dl, grayscale detected only 40% of the malignant lesions, whereas Doppler imaging detected 10%. Conditional logistic regression was performed to evaluate the use of gray-scale and Doppler imaging (color and power) in patients with proven prostatic cancer. Each variable showed a significant positive correlation with cancer when it was included as the only independent variable (gray-scale: odds ratio = 1.9, p = 0.014; Doppler: odds ratio = 3.7, p < 0.001). When both variables were simultaneously included, a positive correlation was seen for gray-scale (odds ratio = 1.4, 95% confidence interval [CI] = ) and Doppler flow (odds ratio = 3.2, 95% CI = ), but only Doppler flow was significant (p = 0.003). The distribution of Gleason scores among malignant specimens with sufficient tissue for grading is summarized in Table 2. The mean Gleason score was 6.5 among foci with no associated gray-scale abnormality and 7.0 among foci with gray-scale findings. The mean Gleason score was 6.6 among cancerous foci with no Doppler flow and 7.0 among cancerous foci with Doppler flow. The chi-square test for trend was significant (χ = 6.3, p = 0.012) for tumor grade as a function of gray-scale abnormality but was not significant for tumor grade versus Doppler flow (χ = 2.9, p = 0.086). Among 41 patients in the baseline group who were examined with color Doppler imaging, 48 foci with cancer were found in 16 patients. Among 210 subsequent patients examined with power Doppler imaging, 163 foci with cancer were found in 69 patients. Average Gleason Fig. 1. Adenocarcinoma of prostate involving left base and left mid gland in 73-year-old man. Gleason score was 7 (3 + 4). Transverse gray-scale sonogram shows large hypoechoic mass on left (arrows) with associated bulge of posterolateral prostatic contour. Power Doppler shows increased flow within and around hypoechoic tumor. 624 AJR:174, March 2000
3 Sonographic Detection of Prostatic Cancer Fig. 2. Adenocarcinoma of the prostatic base with bilateral involvement in 61-year-old man. Gleason score was 6 (3 + 3). A, Transverse color sonogram shows increased parenchymal flow on right. Left-sided flow is predominantly in capsular vessels and neurovascular bundle. B, Transverse power sonogram also shows increased flow on right side. A B score in both groups was 6.7. The populations were similar in terms of age and PSA level. Color Doppler imaging yielded 14.6% sensitivity and 93.9% specificity (κ = 0.11), whereas power Doppler imaging yielded 30.7% sensitivity and 74.0% specificity (κ = 0.03). Conditional logistic regression with both gray-scale and Doppler sonography as independent variables showed a positive correlation of cancer with color flow (odds ratio = 3.9, p = 0.15) and power Doppler (odds ratio = 2.9, p = 0.015). The lack of significance for color Doppler was related to small sample size in the baseline group. A comparison of results for radiologists and urologists is provided in Table 3. With respect to gray-scale imaging, the sensitivity of radiologists was 44.4% with a specificity of 70.5% (κ = 0.12). The sensitivity of urologists was 37.5% with a specificity of 79.8% (κ = 0.13). With power Doppler imaging, the sensitivity of radiologists was 27.3% with a specificity of 83.9% (κ = 0.09). The sensitivity of urologists was 35.9% with a specificity of 59.3% (κ = 0.03). Agreement between power Doppler and pathology results was significantly better for the radiologists than for the urologists (p < 0.002). With the exception of power Doppler interpretation by the urologists, the remaining kappa values in this study were significant (p < 0.05). Conditional logistic regression analysis AJR:174, March
4 Halpern and Strup Gray-Scale and Doppler TABLE 1 Detection of Prostatic Cancer by Biopsy Site in 251 Patients Sonographic Findings Benign Malignant Gray-scale sonography Normal findings Abnormal findings Doppler sonography No flow Increased flow TABLE 2 Sonographic Findings Gray-Scale and Doppler Detection of Prostatic Cancer by Biopsy Site, Stratified by Gleason Score Gleason Score Gray-scale sonography Normal findings Abnormal findings Doppler sonography No flow Increased flow Gray-scale and Doppler sonography Normal findings Gray-Scale and Power Doppler Detection of TABLE 3 Prostatic Cancer Stratified by Radiologists Versus Urologists Sonographic Findings Benign Malignant Radiologists Gray-scale sonography Normal findings Abnormal findings Power Doppler sonography No flow Increased flow Urologists Gray-scale sonography Normal findings Abnormal findings Power Doppler sonography No flow Increased flow of gray-scale and power Doppler was repeated for the subgroup of patients examined by radiologists, showing a positive correlation for both gray-scale (odds ratio = 1.8, p = 0.14) and power Doppler (odds ratio = 4.7, p = 0.007). Discussion On the most basic level, sonography may be used to direct biopsy samples from all parts of the gland. A more advanced role of sonography is to select and target biopsy sites with cancerous foci. In this role, sonography might be used to limit the number of biopsy sites per patient or even to limit the number of patients subjected to biopsy. Although our results do not provide a direct comparison of targeted and sextant biopsy strategies, our results do indicate that gray-scale and Doppler evaluation fail to identify many malignant lesions found on sextant biopsy. Because the trend at many centers is to obtain a larger number of biopsy samples (i.e., saturation biopsies), a strategy that relies only on a limited number of targeted biopsies will miss some malignant lesions. Is the effort required for diagnostic sonography of the prostate justified? Even among patients with an elevated PSA level ( 10 ng/ml) who might be expected to have larger tumor burdens, sonography showed low sensitivity. Furthermore, sonography failed to detect 35 of 99 cancerous foci with a Gleason score of 7 or higher (Table 2). The results of a recent study comparing sextant and targeted biopsy in 194 patients revealed that additional malignant lesions were not detected with targeted biopsy [15]. Nonetheless, regression analysis suggests that gray-scale and Doppler sonography are useful to select biopsy sites in patients with cancer. Thus, although normal sonographic findings should not preclude biopsy, regions with gray-scale or Doppler abnormality may be preferentially sampled in patients with limited tolerance or at high risk for multiple biopsies. The urologists in our study had no prior experience with color or power Doppler sonography. Although the urologists performed as well as the radiologists with gray-scale imaging, kappa analysis suggests that the radiologists were more accurate with power Doppler imaging (p < 0.002). Clearly, there is a learning curve for power Doppler imaging. However, even for the radiologists, there was no diagnostic advantage to using power Doppler (κ = 0.09) over color Doppler (κ = 0.11) in the diagnosis of prostatic cancer. An association has been shown between increased microvessel density in prostatic cancer and the presence of metastases [16], the stage of disease [17 19], and disease-specific survival [20, 21]. Indeed, increased color flow correlates with tumor stage and grade as well as with risk of recurrence after treatment [22]. If microvascular density is increased in prostatic cancer, why do color and power Doppler imaging fail to detect malignant lesions? The key to this discrepancy may be related to the size and distribution of microvessels in prostatic cancer. Although there are more vessels in malignant prostate tissue, the distribution of these microvessels is more uniform [23] and these vessels are smaller [24]. The total intravascular volume in malignant tissue may not be much greater than that found in benign tissue [21]. Because microvessels are below the limit of resolution of color and power Doppler imaging, larger feeder vessels, which supply vascular beds of similar volumes in benign and malignant prostate tissue, are predominantly visualized with color and power Doppler imaging. Several limitations of this study should be acknowledged. Imaging findings were prospectively interpreted at the time of the study, but the examining physician was not blinded to clinical and laboratory information. The number of patients in the baseline color Doppler imaging group was small. All examinations were performed with the Sonoline Elegra system. Although this system provides high-quality imaging, our results may not necessarily be generalized to other instruments or imaging techniques. In conclusion, although there are structural differences in the architecture of benign and malignant prostate tissue, gray-scale and color and power Doppler sonography do not adequately distinguish these features. Future research on diagnostic imaging of prostatic cancer should address parameters that might distinguish known microscopic differences in glandular and microvessel patterns. References 1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, CA Cancer J Clin 1999;49: Bree RL. The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997;49[suppl 3A]: Plawker MW, Fleisher JM, Vapnek EM, Macchia RJ. Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol 1997;158: Rifkin MD, Dahnert W, Kurtz AB. State of the art: endorectal sonography of the prostate gland. AJR 1990;154: Dahnert WF, Hamper UM, Eggleston JC, et al. Prostatic evaluation by transverse sonography with histo- 626 AJR:174, March 2000
5 Sonographic Detection of Prostatic Cancer pathologic correlation: echogenic appearance of early carcinoma. Radiology 1986;158: Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results and potential applications of color Doppler US scanning. Radiology 1993;186: Sudakoff GS, Smith R, Vogelzang NJ. Color Doppler imaging and transrectal sonography of the prostate fossa after radical prostatectomy: early experience. AJR 1996;167: Lavoipierre AM, Snow RM, Frydenberg M. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR 1998;171: Kelly IMG, Lees WR, Rickards D. Prostate cancer and the role of color Doppler US. Radiology 1993;189: Newman JS, Bree RL, Rubin JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology 1995;195: Cornud F, Belin X, Piron D, et al. Color Dopplerguided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for non-palpable lesions. Urology 1997;49: Bude RO, Rubin JM. Power Doppler sonography. Radiology 1996;200: Cho JY, Kim SH, Lee SE. Diffuse prostatic lesions: role of color Doppler and power Doppler ultrasonography. J Ultrasound Med 1998;17: Okihara K, Kojima M, Naya Y, Iida A, Watanabe M, Watanabe H. Ultrasonic power Doppler imaging for prostatic cancer: a preliminary report. Tohoku J Exp Med 1997;182: Blake MA, Barish MA, Fenlon HF, Pomeroy O, Kuligowska E. Transrectal ultrasound (TRUS) detection of prostate cancer: comparison of sextant versus targeted biopsy. J Ultrasound Med 1999;18:S Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143: Fregene TA, Khanuja PS, Noto AC, et al. Tumorassociated angiogenesis in prostate cancer. Anticancer Res 1993;13: Brawer MK, Deering RE, Brown M, et al. Predictors of pathologic stage in prostate carcinoma. The role of neovascularity. Cancer 1994;73: Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48: Lissbrant IF, Stattin P, Damber JE, et al. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33: Borre M, Offersen BV, Nerstrom B et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78: Ismail M, Petersen RO, Alexander AA, et al. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 1997;50: Kay PA, Robb RA, Bostwick DG. Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis. Prostate 1998; 37: Louvar E, Littrup PJ, Goldstein A, et al. Correlation of color flow in the prostate with tissue microvascularity. Cancer 1998;83: AJR:174, March
6 Halpern and Strup 628 AJR:174, March 2000
JMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More informationEffect of Dutasteride Therapy on Doppler US Evaluation of Prostate: Preliminary Results 1
Genitourinary Imaging Elizabeth P. Ives, MD Leonard G. Gomella, MD Ethan J. Halpern, MD Published online 10.1148/radiol.2371041543 2005; 237:197 201 Abbreviations: BPH benign prostatic hyperplasia PSA
More informationAdvances in Ultrasound for the Detection of Prostate Cancer
Ultrasound Quarterly Vol. 18, No. 2, pp. 135 142 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Advances in Ultrasound for the Detection of Prostate Cancer Ferdinand Frauscher, M.D.,* Andrea Klauser,
More informationHypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings
Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,
More informationAward Number: DAMD TITLE: Intermittent Ultrasound Imaging of Prostate Cancer. PRINCIPAL INVESTIGATOR: Ethan J. Halpem, M.D.
AD Award Number: DAMD17-01-1-0061 TITLE: Intermittent Ultrasound Imaging of Prostate Cancer PRINCIPAL INVESTIGATOR: Ethan J. Halpem, M.D. CONTRACTING ORGANIZATION: Jefferson Medical College Philadelphia,
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationCan Color Doppler Sonography Aid in the Prediction of Malignancy of Thyroid Nodules?
Article Can Color Doppler Sonography Aid in the Prediction of Malignancy of Thyroid Nodules? Mary C. Frates, MD, Carol B. Benson, MD, Peter M. Doubilet, MD, PhD, Edmund S. Cibas, MD, Ellen Marqusee, MD
More informationAdvances in Bioscience and Clinical Medicine ISSN:
Advances in Bioscience and Clinical Medicine ISSN: 2203-1413 www.abcmed.aiac.org.au Original Paper Role of Duplex Ultrasound in Diagnosis of Prostate Cancer and Localization for Biopsy Iman Yazdaninia,
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationDiagnostic TRUS Elastography of the Prostate
Diagnostic TRUS Elastography of the Prostate George Zacharopoulos Department of Diagnostic Ultrasound Hygeia Hospital Athens, Greece Prostate HI-RTE Why we need Elastography Better Detection of possible
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationOwing to the widespread use of prostate specific antigen (PSA)
ORIGINAL RESEARCH Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation Moamen M. Amin, MD; Suganthiny Jeyaganth, MSc; Nader Fahmy,
More informationThe In uence of Prostate Volume on Prostate Cancer Detection
European Urology Supplements European Urology Supplements 1 (2002) 35±39 The In uence of Prostate Volume on Prostate Cancer Detection Michael K. Brawer * Northwest Prostate Institute, Seattle, USA Abstract
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationProstate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)
Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate
More informationDutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate Biopsy Increases Prostate Cancer Detection
european urology 53 (2008) 112 117 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Dutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate
More informationSonographic Features of Benign Thyroid Nodules
Article Sonographic Features of Benign Thyroid Nodules Interobserver Reliability and Overlap With Malignancy Jeffrey R. Wienke, MD, Wui K. Chong, MD, Julia R. Fielding, MD, Kelly H. Zou, PhD, Carol A.
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationActive Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof?
Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Duke Bahn MD Prostate Institute of America, Ventura, California INTRODUCTION In the November
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationSocio-demographic profile of prostatic diseases in symptomatic patients: a prospective cross-sectional study
International Journal of Advances in Medicine Praveenkumar P et al. Int J Adv Med. 2015 May;2(2):138-143 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Research Article DOI: 10.5455/2349-3933.ijam20150512
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationComparison Of Accuracy Of Prostate Model Volume Measurement Between 2 Dimensional And 3 Dimensional Ultrasonography.
ISPUB.COM The Internet Journal of Radiology Volume 14 Number 2 Comparison Of Accuracy Of Prostate Model Volume Measurement Between 2 Dimensional And 3 Dimensional Ultrasonography. S Park, S Hwang Citation
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationONCOLOGY LETTERS 8: , 2014
1834 Systematic 12 and 13 core transrectal ultrasound or magnetic resonance imaging guided biopsies significantly improve prostate cancer detection rate: A single center 13 year experience GONG CHENG *,
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationCurrent Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR
BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)
More informationValue of Power Doppler and 3D Vascular Sonography as a Method for Diagnosis and Staging of Prostate Cancer
European Urology European Urology 44 (2003) 21 31 Value of Power Doppler and 3D Vascular Sonography as a Method for Diagnosis and Staging of Prostate Cancer J.L. Sauvain a,*, P. Palascak b, D. Bourscheid
More informationI have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationLymph Node Hilus. Gray Scale and Power Doppler Sonography of Cervical Nodes. Article
Article Lymph Node Hilus Gray Scale and Power Doppler Sonography of Cervical Nodes Anil Ahuja, FRCR, Michael Ying, MPhil, Ann King, FRCR, Hok Yuen Yuen, FRCR Objective. To investigate the difference in
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationProstate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX
Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don
More informationProblems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.
Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationTransrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital
R E V I E W A R T I C L E Transrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital Yuh-Shyan Tsai 1,2, Chia-Horng Chen 3, Yi-Hsiang Lin 4, Tzong-Shin Tzai 1
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationS1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES
Prostate Cancer Histopathology Reporting Proforma (Radical Prostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth Indigenous
More informationASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES
ASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES I. E. PLEŞEA*, B. ZAHARIA*, S. D. ENACHE**, G. MITROI***, P. TOMESCU***, O. T. POP*, P. BADEA****, A. KOŻOKIĆ***** *Department
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationDifferential Diagnosis of Focal Epididymal Lesions With Gray Scale Sonographic, Color Doppler Sonographic, and Clinical Features
Article Differential Diagnosis of Focal Epididymal Lesions With Gray Scale Sonographic, Color Doppler Sonographic, and Clinical Features Dal Mo Yang, MD, Sun Ho Kim, MD, Ha Na Kim, MD, Jee Hee Kang, MD,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationContrast-enhanced ultrasonography for the detection and characterization of prostate cancer: Correlation with microvessel density and Gleason score
Clinical Radiology 66 (2011) 732e737 Contents lists available at ScienceDirect Clinical Radiology journal homepage: www.elsevierhealth.com/journals/crad Original Paper Contrast-enhanced ultrasonography
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationprostate cancer diagnosis and patient management
Isabelle oulay-oletta, M Groupe hospitalier Paris Saint-Joseph (St. Joseph Hospital) in Paris, France Synthetic diffusion: a robust sequence for prostate cancer diagnosis and patient management Located
More informationUltrasonographically Guided Biopsy of the Prostate Gland
Review Article Ultrasonographically Guided Biopsy of the Prostate Gland Andrew L. Altman, MD, Martin I. Resnick, MD Abbreviations BPH, benign prostatic hyperplasia; PIN, prostatic intraepithelial neoplasia;
More informationStephen McManus, MD David Levi, MD
Stephen McManus, MD David Levi, MD Prostate MRI Indications INITIAL DETECTION, STAGING, RECURRENT TUMOR LOCALIZATION, RADIATION THERAPY PLANNING INITIAL DETECTION Clinically suspected prostate cancer before
More informationProstate cancer staging and datasets: The Nitty-Gritty. What determines our pathological reports? 06/07/2018. Dan Berney Maastricht 2018
Prostate cancer staging and datasets: The Nitty-Gritty What determines our pathological reports? Dan Berney Maastricht 2018 Biopsy reporting. How not to do it. The TNM 8 th edition. Changes good and bad
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationProstate cancer smart screening, precision diagnosis, personalised treatment'
Prostate cancer smart screening, precision diagnosis, personalised treatment' Prof. Hashim Ahmed PhD, FRCS(Urol), BM, BCh (Oxon), BA(Hons) Consultant Urological Surgeon Bupa Cromwell Hospital Clinics:
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationThe TRUS guided prostate extended biopsy in the detection of prostate cancer
Mædica - a Journal of Clinical Medicine ORIGIN RIGINAL PAPERS The TRUS guided prostate extended biopsy in the detection of prostate cancer Assoc. Prof. V. AMBERT, MD, PhD; A. ATEIA, MD; I. CHIRA, MD, PhD;
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationUtility of Prostate MRI. John R. Leyendecker, MD
Utility of Prostate MRI John R. Leyendecker, MD Professor of Radiology and Urology Executive Vice Chair of Clinical Operations Section Head, Abdominal Imaging Wake Forest University School of Medicine;
More informationBLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER
BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.
More informationDiagnosis, pathology and prognosis including variant pathology
PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More information3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education
More informationOMPRN Pathology Matters Meeting 2017
OMPRN Pathology Matters Meeting 2017 Pathology of Aggressive Prostate Cancer Intraductal Carcinoma and Cribriform Carcinoma Dr. Michelle Downes, Staff Urologic Pathologist Sunnybrook Health Sciences Centre,
More informationA re-audit of Prostate biopsies from January to December 2010 and 2013.
A re-audit of Prostate biopsies from January to December 2010 and 2013. Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees Stockton on Tees. Objectives To assess and compare
More informationThe Frequency and Significance of Small (15 mm) Hepatic Lesions Detected by CT
535 Elizabeth C. Jones1 Judith L. Chezmar Rendon C. Nelson Michael E. Bernardino Received July 22, 1991 ; accepted after revision October 16, 1991. Presented atthe annual meeting ofthe American Aoentgen
More informationPI-RADS classification: prognostic value for prostate cancer grading
PI-RADS classification: prognostic value for prostate cancer grading Poster No.: C-1622 Congress: ECR 2014 Type: Scientific Exhibit Authors: I. Platzek, A. Borkowetz, T. Paulus, T. Brauer, M. Wirth, M.
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationBrief History. Identification : Past History : HTN without regular treatment.
Brief History Identification : Name : 陳 x - Admission : 94/10/06 Gender : male Age : 75 y/o Chief Complaint : Urinary difficulty for months. Past History : HTN without regular treatment. Brief History
More informationMONA V. SANGHANI, DELRAY SCHULTZ, CLARE M. TEMPANY, DAVID TITELBAUM, ANDREW A. RENSHAW, MARIAN LOFFREDO, KERRI COTE, BETH MCMAHON,
ADULT UROLOGY QUANTIFYING THE CHANGE IN ENDORECTAL MAGNETIC RESONANCE IMAGING-DEFINED TUMOR VOLUME DURING NEOADJUVANT ANDROGEN SUPPRESSION THERAPY IN PATIENTS WITH PROSTATE CANCER MONA V. SANGHANI, DELRAY
More informationeuropean urology 54 (2008)
european urology 54 (2008) 1354 1362 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography:
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationImaging of prostate cancer local recurrences : why and how?
Imaging of prostate cancer local recurrences : why and how? Olivier Rouvière Department of Urinary and Vascular Imaging Hospices Civils de Lyon Lyon - France 1. Preliminary Remarks Preliminary Remarks
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationDiagnostic benefits of ultrasound-guided. CNB) versus mammograph-guided biopsy for suspicious microcalcifications. without definite breast mass
Volume 118 No. 19 2018, 531-543 ISSN: 1311-8080 (printed version); ISSN: 1314-3395 (on-line version) url: http://www.ijpam.eu ijpam.eu Diagnostic benefits of ultrasound-guided biopsy versus mammography-guided
More informationShear Wave Elastography for Detection of Prostate Cancer: A Preliminary Study
Original Article Genitourinary Imaging http://dx.doi.org/10.3348/kjr.2014.15.3.346 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(3):346-355 Shear Wave Elastography for Detection of Prostate Cancer:
More informationProstate Cancer DFP Case of the Week
Prostate Cancer DFP Case of the Week Antonio C. Westphalen, MD PhD Clinical Prostate MR Imaging Program, Director Associate Professor of Radiology and Urology University of California, San Francisco Case
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationSonographic Differentiation of Thyroid Nodules With Eggshell Calcifications
Article Sonographic Differentiation of Thyroid Nodules With Eggshell Calcifications Byung Moon Kim, MD, Min Jung Kim, MD, Eun-Kyung Kim, MD, Jin Young Kwak, MD, Soon Won Hong, MD, Eun Ju Son, MD, Ki Hwang
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationPoor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA
https://doi.org/10.1007/s00345-018-2252-4 TOPIC PAPER Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA Stig Müller 1,2 Gunder Lilleaasen 1 Tor Erik
More informationIt is time to abandon transrectal prostate biopsy for perineal biopsy. Con Argument
It is time to abandon transrectal prostate biopsy for perineal biopsy Con Argument Erik P. Castle M.D., F.A.C.S. Professor of Urology Mayo Clinic Department of Urology Phoenix, AZ None Financial Disclosures
More informationMagnetic resonance imaging predictors of extracapsular extension of prostate cancer: Do they accurately reflect pt3 staging?
Magnetic resonance imaging predictors of extracapsular extension of prostate cancer: Do they accurately reflect pt3 staging? Poster No.: C-1399 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More information